Titre |
A retrospective observational study to
assess imaging and management of
patients with castration-resistant
prostate cancer |
Protocole ID |
AMGEN 20150126 |
ClinicalTrials.gov ID |
|
Type(s) de cancer |
Prostate |
Phase |
Autres |
Institution |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
1001 boul. Décarie , Montréal, QC, H4A 3J1
|
Ville |
Montréal |
Investigateur(trice) principal(e) |
Dr Armen Aprikian
|
Coordonnateur(trice) |
Maria Simona Grigorie
514-934-1934 poste 35160
|
Statut |
Actif en recrutement |
Date d'activation |
27-05-2016 |
Critètes d'éligibilité |
-
Men diagnosed with castration-resistant prostate cancer, defined as a recorded PSA
-
value of ≥2 ng/mL despite ongoing androgen deprivation therapy (ADT)
-
Patient has completed at least one follow-up clinic visit subsequent to the development of castration-resistance (the date of this clinic visit defines the index date)
-
Age ≥18 years at index date
-
Patient can have prior or current evidence of detectable bone or visceral metastasis(es) and MUST have completed at least one additional follow-up visit subsequent to the identification of bone/visceral metastases and the patient’s chart contains details of this follow-up visit
|
Critètes d'exclusion |
-
Patient had evidence of detectable bone or visceral metastasis(es) at index date
-
Patient has received investigational agent(s) or completed investigational procedures as part of a non-metastatic CRPC clinical study protocol
|